PMID- 36254014
OWN - NLM
STAT- MEDLINE
DCOM- 20221019
LR  - 20221115
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 41
DP  - 2022 Oct 14
TI  - Study on the protective mechanism of dexmedetomidine on the liver of 
      perioperative diabetic patients: A randomized controlled trial.
PG  - e30899
LID - 10.1097/MD.0000000000030899 [doi]
LID - e30899
AB  - BACKGROUND: Although several studies have reported that dexmedetomidine is a 
      highly selective alpha2-adrenergic receptor agonist that protects liver function in 
      perioperative patients by inhibiting oxidative stress (OS) and inflammatory 
      response, patients with type 2 diabetes mellitus (T2DM) have not been included in 
      the previous studies. The purpose of this study was to investigate the effects of 
      perioperative low-dose dexmedetomidine on perioperative liver function in T2DM 
      patients. METHODS: This was a single-center, placebo-controlled randomized trial. 
      Fifty-four T2DM patients scheduled for debridement of lower extremity ulcers were 
      included in this study and randomly divided into 2 groups (n = 27 per group): the 
      dexmedetomidine group (DEX group) and the control group (CON group). Continuous 
      intravenous infusion of dexmedetomidine (DEX group) or normal saline (CON group) 
      was administered from the completion of monitoring to the end of surgery. All 
      participants received femoral and sciatic nerve block with 0.33% ropivacaine. The 
      main result was the activity of liver enzymes (AST, ALT) reflecting liver 
      function. The secondary results included variables reflecting blood glucose 
      (Glu), blood lipids (TG, HDL, LDL, total cholesterol), biomarkers of OS (MDA, 
      SOD), and systemic inflammatory response (TNF-alpha, IL-6). RESULTS: Compared with 
      CON group, DEX group exhibited a reduction in hemodynamic parameters, Glu, 
      systemic inflammatory response, and liver injury indicators. OS response MDA 
      activity was lower in DEX group than in CON group, while SOD was higher than that 
      in CON group. The variables reflecting lipid metabolism function showed no 
      differences between the groups. CONCLUSION SUBSECTIONS: Dexmedetomidine 
      administered perioperatively can reduce Glu levels and protect the liver by 
      attenuating OS injury and inflammatory response in T2DM patients without any 
      potential risk.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zeng, Lin
AU  - Zeng L
AUID- ORCID: 0000-0001-9365-9856
AD  - Shifang People's Hospital, Shifang, Sichuan Province, China.
FAU - Liu, Juan
AU  - Liu J
AD  - Clinical Medical College and The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, China.
FAU - Zhang, Tianyao
AU  - Zhang T
AD  - Clinical Medical College and The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, China.
FAU - Liu, Yusong
AU  - Liu Y
AD  - Shifang People's Hospital, Shifang, Sichuan Province, China.
FAU - Liao, Lumiu
AU  - Liao L
AD  - Clinical Medical College and The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, China.
FAU - Chen, Xuelian
AU  - Chen X
AD  - Clinical Medical College and The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, China.
FAU - Dong, Shuhua
AU  - Dong S
AD  - Clinical Medical College and The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Adrenergic alpha-2 Receptor Agonists)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Interleukin-6)
RN  - 0 (Saline Solution)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - 7IO5LYA57N (Ropivacaine)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Adrenergic alpha-2 Receptor Agonists/therapeutic use
MH  - Biomarkers
MH  - Blood Glucose
MH  - Cholesterol
MH  - *Dexmedetomidine
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Interleukin-6
MH  - Liver/surgery
MH  - Ropivacaine
MH  - Saline Solution
MH  - Superoxide Dismutase
MH  - Systemic Inflammatory Response Syndrome/drug therapy
MH  - Tumor Necrosis Factor-alpha
PMC - PMC9575753
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/10/19 06:00
MHDA- 2022/10/20 06:00
PMCR- 2022/10/14
CRDT- 2022/10/18 01:32
PHST- 2022/10/18 01:32 [entrez]
PHST- 2022/10/19 06:00 [pubmed]
PHST- 2022/10/20 06:00 [medline]
PHST- 2022/10/14 00:00 [pmc-release]
AID - 00005792-202210140-00046 [pii]
AID - 10.1097/MD.0000000000030899 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Oct 14;101(41):e30899. doi: 
      10.1097/MD.0000000000030899.